Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $15.60

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $15.60.

Several brokerages recently weighed in on YMAB. Truist Financial lowered their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. HC Wainwright lowered their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating for the company in a report on Monday, May 19th. Oppenheimer lowered their price objective on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, May 29th. Finally, Wedbush reissued an "outperform" rating and issued a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of YMAB. Acorn Capital Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter valued at $22,408,000. Caligan Partners LP raised its stake in Y-mAbs Therapeutics by 47.9% during the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company's stock valued at $13,843,000 after purchasing an additional 572,729 shares during the period. Infinitum Asset Management LLC acquired a new stake in Y-mAbs Therapeutics during the 4th quarter valued at $1,218,000. Paradigm Biocapital Advisors LP raised its stake in Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company's stock valued at $33,171,000 after purchasing an additional 150,000 shares during the period. Finally, AQR Capital Management LLC raised its stake in Y-mAbs Therapeutics by 869.3% during the 1st quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock valued at $730,000 after purchasing an additional 147,788 shares during the period. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Trading Down 1.9%

Shares of YMAB traded down $0.08 during midday trading on Friday, reaching $4.22. 168,824 shares of the company were exchanged, compared to its average volume of 297,944. The stock has a 50-day moving average price of $4.47 and a 200-day moving average price of $5.28. The company has a market cap of $191.08 million, a price-to-earnings ratio of -6.59 and a beta of 0.51. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 30.59% and a negative net margin of 31.84%. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Equities research analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.